NCT05032196已完成1 期
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease (SELECT-HD)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 45
- 主要终点
- Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug
研究概览
简要总结
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of WVE-003 in adult patients with early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) - SNP3.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 25 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of the A variant of SNP3 on the same allele as the pathogenic CAG triplet expansion
- •Ambulatory, male or female patients aged ≥25 to ≤60 years
- •Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4
- •UHDRS Total Functional Capacity Scores ≥9 and ≤13
排除标准
- •Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years
- •Received any other study drug, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer, with the exception of the following:
- •a. Received WVE-120101 or WVE-120102 within the last 3 months
- •Implantable CNS device that may interfere with ability to administer study drug via lumbar puncture or undergo MRI scan
- •Inability to undergo brain MRI (with or without sedation)
- •Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture
- •Previously received tominersen
结局指标
主要结局
Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug
时间窗: Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2)
The primary outcome for this study was safety and is reported as the proportion of patients with TEAEs related to study drug.
次要结局
- Pharmacokinetics of WVE-003 in Plasma(Day 1 (single ascending dose Period 1); Day 1 and Day 113 (multi dose Period 2))
- Concentration of WVE-003 in Cerebrospinal Fluid (CSF)(28 days post-dose during Period 1 (P1:Day29); 28 days post last dose during Period 2 (P2: Day141))
研究者
研究点 (45)
Loading locations...
相似试验
终止
1 期
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)ALSFTDNCT04931862Wave Life Sciences Ltd.35
已完成
1 期
GB004 in Adult Subjects With Active Ulcerative ColitisUlcerative ColitisNCT03860896GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.34
已完成
2 期
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic SteatohepatitisNASH - Nonalcoholic SteatohepatitisNCT05415722Terns, Inc.162
尚未招募
2 期
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese AdultsOverweight and ObesityNCT06500299Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.180
已完成
2 期
A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal PolypsChronic SinusitisNasal PolypsNCT06036927Chia Tai Tianqing Pharmaceutical Group Co., Ltd.80